Cargando…

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease

Sickle cell disease (SCD) is a chronic hemolytic anemia affecting millions worldwide with acute and chronic clinical manifestations and early mortality. While hydroxyurea (HU) and other treatment strategies managed to ameliorate disease severity, high inter-individual variability in clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pandey, Akancha, Estepp, Jeremie H., Raja, Rubesh, Kang, Guolian, Ramkrishna, Doraiswami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144420/ https://www.ncbi.nlm.nih.gov/pubmed/35631651 http://dx.doi.org/10.3390/pharmaceutics14051065

Ejemplares similares

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease
por: Pandey, Akancha, et al.
Publicado: (2023)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach
por: Alberts, Nicole M, et al.
Publicado: (2020)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

High bias and low precision for estimated versus measured glomerular filtration rate in pediatric sickle cell anemia
por: Lebensburger, Jeffrey D., et al.
Publicado: (2020)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision
por: Creary, Susan, et al.
Publicado: (2015)

Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
por: Korubo, Kaladada I., et al.
Publicado: (2021)

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

Erratum: Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease: Report from 3 Centers
Publicado: (2021)

P-048: INFLUENCE OF SEVEN GENETIC POLYMORPHISMS ON THE RESPONSE TO SICKLE CELL DISEASE THERAPY WITH HYDROXYUREA
por: O., FRANCO SANTOS, et al.
Publicado: (2022)

Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis
por: Kirkham, Justin K., et al.
Publicado: (2023)

Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review
por: Yang, Mira, et al.
Publicado: (2022)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

A model to rate strategies for managing disease due to COVID-19 infection
por: Wang, Shiyan, et al.
Publicado: (2020)

Survival and mortality among users and non-users of hydroxyurea with sickle cell disease
por: de Araujo, Olinda Maria Rodrigues, et al.
Publicado: (2015)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
por: Mnika, Khuthala, et al.
Publicado: (2019)

Effect of Hydroxyurea Treatment on the Inflammatory Markers Among Children With Sickle Cell Disease
por: Zahran, Asmaa M., et al.
Publicado: (2020)

Neutrophils remain detrimentally active in hydroxyurea-treated patients with sickle cell disease
por: Barbu, Emilia Alina, et al.
Publicado: (2019)

Hydroxyurea usage awareness among patients with sickle‐cell disease in Saudi Arabia
por: Alsalman, Mortadah, et al.
Publicado: (2021)

Effectiveness of Pharmacokinetic-Guided Hydroxyurea Dose Individualization in Patients with Sickle Cell Anemia: A Mini-Review
por: dos Santos Neres, Joelma Santana, et al.
Publicado: (2023)

Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease
por: Darshana, Thamal, et al.
Publicado: (2021)

A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring
por: Creary, Susan E., et al.
Publicado: (2017)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
por: Gohal, Gassem A, et al.
Publicado: (2022)

The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease
por: Kang, Hyeun Ah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c882auv1ak1fk93ojlpvt19467